Renal & Urinary

Hypocalcemia: workup and management

Clinical Overview and When to Suspect Hypocalcemia

— PTH deficient: post-thyroidectomy/parathyroidectomy, autoimmune hypoparathyroidism, DiGeorge, infiltrative (Wilson, hemochromatosis), hypomagnesemia (functional hypoparathyroidism)

— Vitamin D deficient: nutritional, malabsorption, CKD (↓1-α-hydroxylation), liver disease, anticonvulsants

— Calcium sequestered/chelated: acute pancreatitis (saponification), rhabdomyolysis, tumor lysis syndrome, massive transfusion (citrate), bisphosphonate/denosumab overshoot

— PTH resistance: pseudohypoparathyroidism

— Postoperative neck surgery patient with perioral numbness or carpopedal spasm

— Pancreatitis patient with persistent tetany

— CKD stage 4–5 patient with bone pain, paresthesias

— Patient just started on denosumab, bisphosphonate IV, or cinacalcet

— Alcoholic with seizures and prolonged QT on telemetry

— Mild/asymptomatic (Ca 7.5–8.5): oral repletion outpatient

— Symptomatic or Ca <7.5 mg/dL, or ionized <3.2 mg/dL: IV calcium, telemetry, admit

— QT prolongation, seizures, laryngospasm, tetany: ICU-level monitoring

Board pearl: Always check magnesium alongside calcium. Hypomagnesemia both impairs PTH secretion and induces PTH resistance — you cannot fix the calcium until you fix the magnesium. This is the single most commonly tested Step 3 trap in refractory hypocalcemia stems.

Definition: total serum calcium <8.5 mg/dL or ionized Ca²⁺ <4.6 mg/dL (1.15 mmol/L); ionized is the physiologically active fraction and is the true gold standard when albumin is abnormal or pH shifts are present.

Corrected calcium formula: measured Ca + 0.8 × (4 − albumin). Use when albumin is low to avoid mislabeling pseudohypocalcemia.

Pathophysiologic buckets to keep in your head:

When to suspect on Step 3:

Severity stratification drives disposition:

Presentation Patterns and Key History

— Paresthesias: circumoral, fingertips, toes — earliest and most sensitive

— Muscle cramps, carpopedal spasm, tetany

— Laryngospasm and bronchospasm: medical emergency

— Seizures: generalized tonic-clonic; may occur with normal EEG between events

— Palpitations, presyncope from prolonged QT → torsades

— Decompensated heart failure from impaired excitation-contraction coupling (rare, severe cases)

— Anxiety, irritability, depression, confusion, dementia-like picture in chronic disease

— Basal ganglia calcifications (Fahr syndrome) in long-standing hypoparathyroidism → parkinsonism, chorea

— Recent neck surgery? Total/subtotal thyroidectomy, parathyroidectomy, central neck dissection — timing matters (transient days 1–3 vs permanent at 6 mo)

— Alcohol use, malnutrition, bariatric surgery? → Mg, vitamin D, calcium intake

— CKD or dialysis? Phosphate retention, calcitriol deficiency

— Recent chemotherapy or large tumor burden? Tumor lysis (hyperphosphatemia drives Ca down)

— New medications: denosumab, zoledronic acid, cinacalcet, PPIs (Mg loss), loop diuretics, foscarnet, cisplatin, phenytoin, phenobarbital

— Transfusion >10 units pRBCs? Citrate chelation

— Pancreatitis history or current abdominal pain?

— Family history: autoimmune polyendocrine syndrome type 1, DiGeorge, pseudohypoparathyroidism (short 4th/5th metacarpals, short stature)

Step 3 management: In a post-thyroidectomy patient, obtain Ca and PTH at 6 and 12 hours postop. A PTH <15 pg/mL at 12 h predicts symptomatic hypocalcemia and triggers preemptive oral calcium + calcitriol before discharge, preventing 30-day ED bouncebacks.

Neuromuscular irritability is the dominant symptom cluster because low ionized Ca²⁺ lowers the threshold for nerve depolarization.

Cardiac symptoms:

Neuropsychiatric:

Chronic clues: dry skin, brittle nails, coarse hair, cataracts, dental enamel defects, delayed dentition in kids.

History questions that crack the case:

Physical Exam Findings and Bedside Assessment

— Sensitivity ~25–30%, specificity poor — up to 10–25% of normocalcemic adults are Chvostek-positive. Useful as a trend, not a rule-in.

— More specific (~94%), positive in ~66% of hypocalcemic patients. Better Step 3 sign than Chvostek.

— Hyperreflexia, clonus

— Mental status: confusion, irritability, psychosis in severe/chronic disease

— Papilledema in pseudotumor cerebri (chronic hypoparathyroidism)

— Bradycardia, hypotension, signs of CHF in severe cases

— Auscultate for new murmur if the trigger was endocarditis with septic emboli (rare context)

— Dry, scaly skin; alopecia; brittle ridged nails; candidal infections (think APS-1)

— Cataracts on slit lamp

— Enamel hypoplasia, pitted teeth

— Short stature, round face, short 4th and 5th metacarpals (Archibald sign), obesity, subcutaneous ossifications

— Stridor → impending laryngospasm

— HR irregular → check ECG urgently

— Hypotension unresponsive to fluids → consider Ca-related cardiomyopathy

Key distinction: Chvostek is sensitive-but-nonspecific; Trousseau is specific-but-time-consuming. On the boards, a positive Trousseau in a post-thyroidectomy patient = empiric IV calcium gluconate now, do not wait for the lab value to return. Document the sign in the chart as your clinical trigger.

Chvostek sign: tap the facial nerve ~2 cm anterior to the earlobe along the zygomatic arch → ipsilateral facial twitch (corner of mouth, nasolabial fold).

Trousseau sign: inflate BP cuff 20 mmHg above SBP for 3 minutes → carpal spasm (flexion of MCPs, extension of IPs, adducted thumb).

Neurologic exam:

Cardiac exam:

Skin/appendage exam (chronic):

Skeletal stigmata of pseudohypoparathyroidism (Albright):

Vital signs to flag for escalation:

Diagnostic Workup — Initial Labs, ECG, and Biomarkers

— Repeat total calcium with albumin; calculate corrected Ca

— Order ionized calcium if albumin abnormal, critically ill, transfused, or acid–base disturbance present

— Rule out pseudohypocalcemia from gadolinium interference (recent MRI contrast) or EDTA contamination

— Magnesium (mandatory — see chunk 1)

— Phosphate — high in hypoparathyroidism, CKD, tumor lysis, rhabdo; low in vitamin D deficiency

— Intact PTH — the pivotal branch point

— 25-OH vitamin D (storage form) and 1,25-(OH)₂ vitamin D (active form) in select cases

— Creatinine/BUN — CKD screening

— Alkaline phosphatase — high in vitamin D deficiency/osteomalacia; hungry bone syndrome post-parathyroidectomy

— Lipase, CK if pancreatitis or rhabdo suspected

— LDH, uric acid, K, phosphate for tumor lysis workup

— Low Ca + high PTH + high phosphate + low/normal Cr → vitamin D deficiency or pseudohypoparathyroidism (check 25-OH D)

— Low Ca + high PTH + high phosphate + high Cr → CKD-MBD

— Low Ca + high PTH + low phosphate → vitamin D deficiency confirmed

— Low Ca + low/inappropriately normal PTH + high phosphate → hypoparathyroidism (post-surgical, autoimmune, Mg-related)

— Prolonged QTc (corrected QT >450 ms men, >470 ms women) — hallmark

— T-wave flattening or inversion

— Risk of torsades, especially if concurrent hypoK, hypoMg, or QT-prolonging drugs

CCS pearl: In the CCS hypocalcemia case, on arrival order: BMP, Mg, phosphate, ionized Ca, albumin, intact PTH, 25-OH vitamin D, ECG, and place on continuous cardiac monitoring. Reorder Ca/Mg q6h until trending up and symptoms resolve.

Step 1 — Confirm true hypocalcemia:

Step 2 — Core electrolyte and endocrine panel:

Interpretation algorithm (memorize):

ECG (order in every symptomatic patient):

Diagnostic Workup — Advanced and Confirmatory Studies

— 24-hour urine calcium and creatinine: distinguishes autosomal dominant hypocalcemia (ADH, activating CaSR mutation) — paradoxically high urinary Ca despite low serum Ca. Critical to recognize because aggressive Ca repletion causes nephrocalcinosis.

— Urinary cAMP after PTH infusion (Ellsworth-Howard test): distinguishes pseudohypoparathyroidism type 1a (no cAMP response) from type 2 (normal cAMP, abnormal phosphaturic response). Rarely needed clinically but classic boards fodder.

— PTHrP if malignancy-associated metabolic picture is ambiguous

— Genetic testing: GNAS (PHP1a), CaSR (ADH/FHH), AIRE (APS-1), TBX1 (DiGeorge/22q11.2)

— Neck ultrasound post-thyroidectomy if concern for inadvertent parathyroidectomy

— Renal ultrasound in chronic hypoparathyroidism to screen for nephrocalcinosis/nephrolithiasis (especially if treated long-term with calcitriol and Ca)

— DEXA — typically high BMD in untreated hypoparathyroidism (low bone turnover); useful baseline

— Head CT for suspected Fahr syndrome (basal ganglia calcifications) in chronic disease with movement disorder or dementia

— Slit lamp exam for cataracts in chronic hypoparathyroidism

— Abdominal CT if pancreatitis driving severe hypocalcemia

— Chest X-ray if congestive symptoms in severe cardiomyopathy

— Adrenal antibodies, morning cortisol/ACTH stim

— TSH, TPO antibodies

— CBC for pernicious anemia features

— Mucocutaneous candidiasis on exam → classic triad with hypoparathyroidism and adrenal insufficiency

Board pearl: Familial hypocalciuric hypercalcemia (FHH) and ADH are mirror images — both involve the calcium-sensing receptor. ADH presents with hypocalcemia + relatively high urinary calcium and inappropriately normal/low PTH. Do not over-treat ADH — target the low-normal Ca range to avoid kidney injury.

When initial labs don't fit a clean bucket, escalate:

Imaging:

Acute decompensation imaging:

Autoimmune polyendocrine workup (APS-1):

Severity Stratification and First-Line Management Logic

— Asymptomatic, mild (corrected Ca 7.5–8.5 mg/dL): oral repletion, outpatient workup

— Asymptomatic, moderate (Ca 7.0–7.5): oral repletion + active vitamin D; consider observation

— Symptomatic OR Ca <7.0 mg/dL OR ionized <3.2 mg/dL OR QTc prolonged OR seizing/tetany/laryngospasm: IV calcium, admit, telemetry

— Magnesium — replete IV MgSO₄ 1–2 g over 15 min if <1.6, then continuous infusion

— Potassium — concurrent hypoK worsens QT risk

— Acid-base — alkalosis (e.g., overzealous bicarb, hyperventilation) lowers ionized Ca

— Phosphate — if elevated, do not co-infuse calcium and phosphate (metastatic calcification); lower phos first with binders/dialysis

— Calcium gluconate 1–2 g (10–20 mL of 10% solution) IV over 10–20 min in 50–100 mL D5W

— Recheck ionized Ca 1 h after bolus

— Calcium gluconate 0.5–1.5 mg elemental Ca/kg/hr (typically 10 g of Ca gluconate in 1 L D5W or NS, run at 50 mL/hr)

— Recheck Ca q4–6h, titrate to corrected Ca 8.0–8.5

— Calcium carbonate 1–2 g elemental Ca PO TID with meals (take with food for acid-dependent absorption)

— Calcium citrate preferred if on PPI, achlorhydria, or post-bariatric

— Add calcitriol 0.25–0.5 mcg PO BID if hypoparathyroid or CKD (bypasses 1-α-hydroxylation)

— Cholecalciferol (D3) 1000–2000 IU/day if deficient

Step 3 management: Never push IV calcium chloride through a peripheral line — it causes tissue necrosis on extravasation. CaCl is central-line only; use calcium gluconate peripherally. Mislabeling this is a high-yield patient-safety question.

Triage decision tree (use on every presentation):

Always check and correct in parallel:

Initial bolus for symptomatic patients:

Continuous infusion (if persistent symptoms or Ca remains <7.5):

Transition to oral when stable:

Pharmacotherapy — Detailed First-Line Regimens

— Calcium gluconate 10% (1 g = 93 mg elemental Ca): peripheral-safe, slower onset, preferred initial agent

— Calcium chloride 10% (1 g = 273 mg elemental Ca): 3× more elemental Ca per gram, central line only, reserved for cardiac arrest, severe hyperkalemia with arrhythmia, or refractory symptomatic hypocalcemia

— Bolus rate: never exceed 1.5 mL/min of 10% gluconate (risk: bradycardia, asystole, especially in digitalis users)

— Calcium carbonate 40% elemental Ca; cheap; needs acid → with meals; avoid in PPI users

— Calcium citrate 21% elemental Ca; absorbed independent of gastric acid; preferred in PPI/H2 blocker users, post-gastrectomy, CKD

— Max single dose absorbed ≈ 500 mg elemental — divide TID/QID

— Cholecalciferol (D3): for nutritional deficiency, 1000–2000 IU/day maintenance; loading 50,000 IU weekly × 6–8 wk if severe

— Ergocalciferol (D2): similar, slightly less potent

— Calcitriol (1,25-(OH)₂D3): active form, bypasses renal 1-α-hydroxylase — use in hypoparathyroidism, CKD stage 4–5, vitamin D-dependent rickets; dose 0.25–1 mcg/day, monitor for hypercalcemia

— Calcifediol (25-OH D3): intermediate; useful in CKD

— Reduces urinary Ca losses in chronic hypoparathyroidism — limits hypercalciuria/nephrocalcinosis from calcitriol + Ca therapy

— FDA-approved for chronic hypoparathyroidism inadequately controlled on Ca + active D

— Reduces dose of supplements, decreases hypercalciuria

— Specialist-managed; monitor for osteosarcoma signal (boxed warning)

— Oral Mg oxide 400 mg BID-TID for chronic hypomagnesemia; switch to Mg glycinate if diarrhea

Board pearl: In a digoxin user with hypocalcemia and bradyarrhythmia, slow your IV calcium — rapid push can precipitate "stone heart" (digoxin-Ca synergy causing refractory systolic arrest). Dilute and infuse over 30 minutes with continuous ECG.

IV calcium products:

Oral calcium salts:

Vitamin D analogs:

Thiazide diuretic (HCTZ 12.5–25 mg/day):

Recombinant PTH (1-84, palopegteriparatide):

Magnesium:

Procedure-Oriented and Setting-Specific Management

— Day 0–1: check Ca and intact PTH at 6 h and 12 h postop

— PTH <10 pg/mL → high risk of symptomatic hypocalcemia → start calcium carbonate 1 g elemental TID + calcitriol 0.5 mcg BID prophylactically

— Discharge criteria: tolerating PO, stable Ca >8.0, no Trousseau, education on tetany symptoms

— Outpatient labs: Ca and Mg at 48–72 h post-discharge, then weekly until stable, then monthly × 3

— Profound, prolonged hypocalcemia after parathyroidectomy for severe hyperparathyroidism (high preop alk phos, large adenomas, renal HPT)

— Pattern: low Ca, low phos, low Mg, high alk phos (bone avidly remineralizing)

— Treat with aggressive IV Ca infusion for days–weeks, high-dose calcitriol, oral Ca, Mg replacement

— Citrate in stored blood chelates Ca → ionized hypocalcemia

— Empiric calcium gluconate 1–2 g after every 4 units pRBCs or per ionized Ca q30 min in trauma resuscitation

— Manage hyperphosphatemia first (binders, hydration, rasburicase for urate, dialysis if needed)

— Replete Ca only if symptomatic — asymptomatic mild hypocalcemia can be observed to avoid Ca-phos precipitation

CCS pearl: Post-parathyroidectomy patient with Ca 6.8, phos 2.0, alk phos 800 = hungry bone. Order: continuous Ca gluconate drip, IV/PO Mg, calcitriol 1 mcg BID, Ca carbonate 2 g elemental TID with meals, daily Ca/Mg/phos until stable × 48 h.

Post-thyroidectomy/parathyroidectomy (the highest-yield Step 3 scenario):

Hungry bone syndrome:

Massive transfusion protocols:

Acute pancreatitis with tetany: IV Ca gluconate, treat pancreatitis, do not aggressively normalize Ca (saponification ongoing)

Tumor lysis syndrome:

Hemodialysis-associated: adjust dialysate Ca bath, treat CKD-MBD with calcimimetics/active D/binders

Plasmapheresis/citrate apheresis: prophylactic calcium gluconate infusion during procedure

Special Populations — Elderly and Renal/Hepatic Impairment

— Higher baseline risk: vitamin D deficiency (limited sun, reduced skin synthesis, indoor living), poor intake, PPI use, polypharmacy

— Drug list to scrub: PPIs (Mg loss), loop diuretics (Ca wasting), bisphosphonates, denosumab, phenytoin/phenobarbital (accelerate vit D catabolism)

— Falls risk amplified by neuromuscular symptoms and QT prolongation

— Cognitive symptoms may mimic dementia — check Ca/Mg/vit D in new cognitive decline workup

— Goal corrected Ca 8.0–8.5; avoid overshoot (constipation, AKI, nephrolithiasis)

— Pathophysiology: ↓1-α-hydroxylase → low calcitriol → low gut Ca absorption; phosphate retention → FGF23 ↑ → suppresses calcitriol further; secondary hyperparathyroidism

— KDIGO targets: keep corrected Ca in normal range, phos toward normal, PTH 2–9× upper limit of normal in dialysis

— Tools:

– Non-calcium phosphate binders (sevelamer, lanthanum, ferric citrate) preferred over Ca-based binders to limit vascular calcification

– Active vitamin D analogs: calcitriol, paricalcitol, doxercalciferol

– Calcimimetics (cinacalcet, etelcalcetide) — lower PTH but can drop Ca; monitor closely, hold if corrected Ca <8.4

— Dialysate Ca adjustment (2.25–2.5 mEq/L typical)

— Impaired 25-hydroxylation → low 25-OH D

— Cholestasis → fat-soluble vitamin malabsorption → low D and K

— Use calcitriol or calcifediol rather than cholecalciferol if severe liver dysfunction

— Watch coagulopathy — vitamin K deficiency often coexists

— Stop nonessential QT-prolonging drugs (ondansetron, azoles, fluoroquinolones, macrolides, methadone)

— Substitute calcium citrate for carbonate if PPI required

Step 3 management: In CKD stage 4 with corrected Ca 7.6, phos 5.8, PTH 380, do not start calcitriol first — lower phosphate first with diet counseling and non-Ca binder (sevelamer), then add calcitriol once phos <5.5 to prevent vascular calcification.

Elderly:

CKD stage 3b–5/dialysis:

Hepatic impairment:

Polypharmacy reconciliation:

Special Populations — Pregnancy, Pediatrics, and Genetic Syndromes

— Calcium demand rises in 3rd trimester (fetal skeletal mineralization, ~30 g transferred)

— Placental 1-α-hydroxylase increases active vit D — total Ca falls (albumin dilution) but ionized Ca stays normal

— Manage known hypoparathyroidism with calcitriol (preferred — short half-life, titratable) + Ca carbonate/citrate; monitor ionized Ca monthly, then weekly in 3rd trimester and postpartum (requirements drop fast after delivery → hypercalcemia risk)

— Avoid thiazides if possible (fetal hypoglycemia, thrombocytopenia)

— Severe symptomatic hypocalcemia → IV Ca gluconate is safe

— Early (<72 h): prematurity, IDM (maternal diabetes), perinatal asphyxia

— Late (>72 h): high-phosphate formula, maternal vit D deficiency, DiGeorge (22q11.2 deletion) — check for cardiac defects (tetralogy, interrupted arch), absent thymus shadow, dysmorphic facies

— Treat with IV Ca gluconate; long-term workup for cause

— Rickets: bowing of legs, rachitic rosary, craniotabes — low Ca/phos, high alk phos, low 25-OH D

— Vitamin D-dependent rickets type 1 (1-α-hydroxylase mutation): treat calcitriol

— Type 2 (VDR mutation, alopecia): high-dose Ca + calcitriol

— Pseudohypoparathyroidism: short stature, AHO phenotype, often presents in childhood

— DiGeorge (22q11.2): CATCH-22 — Cardiac, Abnormal facies, Thymic hypoplasia, Cleft palate, Hypocalcemia

— APS-1 (AIRE mutation): mucocutaneous candidiasis + hypoparathyroidism + Addison disease

— Autosomal dominant hypocalcemia: activating CaSR — avoid aggressive Ca/D therapy

— Pseudohypoparathyroidism 1a: GNAS imprinting, AHO features, resistance to multiple Gs-coupled hormones (TSH, gonadotropins)

Board pearl: A neonate with hypocalcemic seizures + cardiac murmur + absent thymic shadow on CXR = DiGeorge syndrome. Order FISH for 22q11.2 deletion and consult immunology (avoid live vaccines, irradiate any blood products).

Pregnancy and lactation:

Neonatal hypocalcemia:

Pediatric considerations:

Genetic syndromes:

Complications and Adverse Outcomes

— Laryngospasm — true airway emergency; stridor, inability to phonate; immediate IV Ca, prepare for intubation

— Generalized seizures — may persist until Ca corrected; benzodiazepines as bridge but definitive therapy is calcium

— Torsades de pointes from prolonged QT, especially with concurrent hypoK/hypoMg or QT-prolonging drugs — defibrillate if pulseless, IV Mg 2 g, overdrive pacing

— Decompensated heart failure with reduced ejection fraction — reversible with Ca repletion

— Hypotension unresponsive to fluids

— Tetany, painful muscle cramps, fatigue, work absenteeism

— Mood disorders, cognitive impairment — often missed

— Pseudotumor cerebri — headache, papilledema, vision changes

— Nephrocalcinosis, nephrolithiasis, CKD — paradoxically from treatment with Ca + calcitriol causing hypercalciuria

— Basal ganglia calcifications (Fahr syndrome) → parkinsonism, dystonia, chorea, cognitive decline

— Cataracts — subcapsular, often bilateral

— Dental abnormalities — enamel hypoplasia, delayed eruption, short roots

— Skin/hair changes — dry skin, alopecia, brittle nails

— IV Ca extravasation → tissue necrosis (especially CaCl)

— Hypercalcemia from overshoot — nausea, AKI, altered mental status

— Hypercalciuria even with normal serum Ca on therapy → stones; monitor 24-h urine Ca, keep <300 mg/day

— Soft tissue calcifications if Ca × phos product >55

— Chronic hypoparathyroidism associated with increased CKD progression, fracture (paradox — low turnover bone), cataracts, and infections (APS-1 context)

Key distinction: Hypoparathyroidism patients have high BMD on DEXA but increased fracture risk because of impaired bone remodeling and brittle architecture. Don't be reassured by a normal DEXA — assess overall fracture risk clinically and counsel fall prevention.

Acute, life-threatening:

Subacute:

Chronic (untreated or long-standing hypoparathyroidism):

Treatment-related complications:

Mortality data:

When to Escalate Care — ICU, Consult, Inpatient Triage

— Seizures, laryngospasm, tetany unresponsive to first bolus

— QTc >500 ms or any documented torsades/ventricular ectopy

— Hemodynamic instability or new HF

— Severe ionized Ca <3.0 mg/dL (<0.75 mmol/L)

— Need for continuous Ca infusion >24 h

— Massive transfusion ongoing with refractory ionized hypocalcemia

— Symptomatic hypocalcemia of any severity until 24 h symptom-free on stable regimen

— Post-thyroidectomy/parathyroidectomy with PTH <10 pg/mL or trending Ca <7.5

— Severe hypomagnesemia with refractory hypocalcemia

— Tumor lysis syndrome

— Hungry bone syndrome

— Mild asymptomatic hypocalcemia with identified treatable cause (vit D deficiency, mild post-op)

— Reliable patient, can fill Rx, has follow-up within 72 h, no QT issues

— Endocrinology: confirmed hypoparathyroidism (especially considering recombinant PTH), refractory disease, suspected APS-1, PHP, ADH

— Nephrology: CKD-MBD, dialysis-related, suspected tubular disorder, nephrocalcinosis

— Surgery: known surgical complication, recurrent laryngeal nerve injury concerns, neck hematoma

— Genetics: suspected DiGeorge, GNAS, CaSR, AIRE mutations; family screening

— Cardiology: torsades, sustained QT prolongation, structural cardiomyopathy from chronic disease

— Oncology/Hem: tumor lysis prevention/management

— Detailed handoff at shift change: drip rate, last ionized Ca, last Mg, ECG trend

— Discharge: written dosing schedule, sick day rules, emergency contact, repeat labs within 72 h, PCP appointment within 1–2 weeks

CCS pearl: When advancing the CCS clock in severe hypocalcemia, advance in small increments (2–4 h), not days. Recheck ionized Ca, Mg, ECG between each increment. Skipping ahead a day risks missing torsades or overshoot hypercalcemia and tanks your score.

Immediate ICU/step-down indications:

Floor admission (telemetry) indications:

Outpatient management appropriate:

Consultation triggers:

Transitions of care safety:

Key Differentials — Same-Category (Calcium/Mineral) Causes

— Total Ca low, ionized Ca normal; no symptoms

— Causes: nephrotic syndrome, cirrhosis, malnutrition, malabsorption

— Action: confirm with ionized Ca; do not treat — treat underlying albumin issue

— Low 25-OH D (<20 ng/mL), high PTH, low/normal Ca, low/normal phos, high alk phos

— Cholecalciferol replacement; recheck at 3 mo

— Type 1: low 1-α-hydroxylase → low 1,25-D — treat calcitriol

— Type 2: VDR mutation → high 1,25-D, alopecia — treat high-dose Ca/calcitriol

— Low calcitriol, high phos, high PTH, low Ca; high FGF23

— Treatment: phosphate binders, active D analog, calcimimetics

— Post-surgical — most common cause overall

— Autoimmune — isolated or APS-1

— Infiltrative — hemochromatosis, Wilson, granulomatous, radiation, metastasis

— Genetic — DiGeorge, autoimmune polyendocrine

— High PTH, low Ca, high phos, normal 25-OH D, normal renal function

— Type 1a: AHO phenotype, multiple hormone resistance

— Low Ca, low/inappropriately normal PTH, high urinary Ca

— Avoid overtreatment — risk of nephrocalcinosis

— Low Mg → impaired PTH release + end-organ PTH resistance

— Causes: PPIs, loop diuretics, alcoholism, diarrhea, cisplatin, aminoglycosides

— Replete Mg first, calcium follows

Key distinction: In the workup, the PTH level is the single most discriminating test. Low/normal PTH with low Ca = hypoparathyroidism or Mg deficiency or ADH. High PTH with low Ca = vit D deficiency, CKD, or PTH resistance (pseudohypoparathyroidism). Memorize this fork.

Pseudohypocalcemia (hypoalbuminemia):

Vitamin D deficiency (nutritional, most common globally):

Vitamin D resistance/dependent rickets:

CKD-mineral bone disorder:

Hypoparathyroidism:

Pseudohypoparathyroidism (PTH resistance):

Autosomal dominant hypocalcemia (ADH, activating CaSR):

Hypomagnesemia:

Key Differentials — Other-Category Causes of Symptoms

— Hyperventilation/anxiety: respiratory alkalosis lowers ionized Ca acutely → carpopedal spasm despite normal total Ca. ABG shows high pH, low pCO2. Treat with reassurance, rebreathing.

— Hypomagnesemia alone: can cause tetany, seizures, tremor independent of Ca; check Mg in every "hypocalcemia mimic"

— Hypokalemic periodic paralysis: flaccid weakness, not tetany; check K

— Hypoglycemia: diaphoresis, tremor, AMS — fingerstick glucose

— Seizure disorder: check Ca/Mg/Na before labeling idiopathic epilepsy in a new-onset adult seizure

— Drug withdrawal (alcohol, benzo): tremor, seizures; check Ca too (often coexists in alcoholic)

— Tetanus: muscle spasms, trismus, risus sardonicus — wound history, immunization status

— Strychnine poisoning, organophosphates: environmental/occupational history

— Conversion disorder: diagnosis of exclusion

— Hypokalemia, hypomagnesemia (often coexist with hypocalcemia)

— Drugs: macrolides, fluoroquinolones, azoles, methadone, ondansetron, antipsychotics, antidepressants

— Congenital long QT syndrome

— Hypothyroidism, hypothermia

— Increased ICP, MI

— Peripheral neuropathy (diabetic, B12, alcoholic)

— MS, transient ischemic attack

— Carpal tunnel (focal, positional)

— Hyperventilation

— Primary hypoparathyroidism (Fahr)

— Pseudohypoparathyroidism

— Aging (incidental, often asymptomatic)

— Mitochondrial disease, infections (TORCH), lead poisoning

Board pearl: A young adult with anxiety, perioral numbness, and carpopedal spasm after an argument is more likely hyperventilation-induced respiratory alkalosis than primary hypocalcemia — but still send ionized Ca and Mg because emergency rooms misattribute true hypoparathyroidism to anxiety, with disastrous airway consequences.

Symptoms that mimic hypocalcemic tetany — broaden your differential:

Differential for prolonged QT:

Differential for paresthesias:

Differential for basal ganglia calcification on CT:

Secondary Prevention, Discharge Medications, and Long-Term Plan

— Chronic hypoparathyroidism:

– Calcium 1–2 g elemental PO divided TID with meals

– Calcitriol 0.25–1 mcg PO daily–BID (titrate to corrected Ca 8.0–9.0, low-normal)

– Cholecalciferol 1000–2000 IU/day to maintain 25-OH D >30 ng/mL

– Thiazide (HCTZ 12.5–25 mg) if hypercalciuria develops

– Low-phosphate, low-sodium diet (sodium drives urinary Ca loss)

– Recombinant PTH (palopegteriparatide) if inadequate control

— Vitamin D deficiency:

– Cholecalciferol 50,000 IU weekly × 6–8 wk, then 1000–2000 IU/day maintenance

– Recheck 25-OH D at 3 mo, then annually

— CKD-MBD:

– Phosphate binders with meals (non-Ca-based preferred)

– Active D analog (calcitriol, paricalcitol)

– Calcimimetic if 2°/3° hyperparathyroidism

– Dietary phosphate restriction (~800 mg/day)

— Post-thyroidectomy transient:

– Calcium carbonate 1–2 g elemental TID + calcitriol 0.25–0.5 mcg BID × 2–4 weeks, taper as Ca normalizes and PTH recovers

— Recognize tetany symptoms early; have rescue oral Ca dose

— Avoid loop diuretics, PPIs, bisphosphonates without endocrine input

— Hydrate well; report vomiting/diarrhea (lose oral Ca absorption)

— Carry medical alert bracelet/wallet card

— Dairy, fortified plant milks, leafy greens, sardines

— Avoid excessive caffeine, sodium, oxalate-heavy foods if hypercalciuric

— Adequate vitamin D from food + sun + supplement

— Pneumococcal, influenza, COVID-19 per schedule

— DEXA at baseline and q2–3 years

— Fall prevention assessment annually in elderly

Step 3 management: On discharge from a post-thyroidectomy admission, always schedule a Ca/Mg/PTH check at 72 h and PCP/endocrine follow-up within 1–2 weeks. Provide written dosing card and a 7-day rescue Ca supply. This single instruction set prevents the majority of 30-day readmissions.

Cause-targeted maintenance therapy:

Sick-day rules to teach:

Diet counseling:

Vaccinations and bone health:

Follow-Up, Monitoring Parameters, and Counseling

— 48–72 h: corrected Ca, ionized Ca if available, Mg, phos, creatinine

— 1 week: same labs + symptom check

— 2 weeks: titrate calcitriol/Ca; ensure no overshoot

— Monthly for 3 months, then quarterly once stable

— Corrected Ca, phos, Mg, Cr every 3–6 months

— 24-hour urine Ca and Cr annually (or sooner if dose changed) — target <300 mg/day to limit stone/nephrocalcinosis risk

— 25-OH vitamin D annually

— Renal ultrasound every 5 years (or sooner if hypercalciuria)

— DEXA q2–3 years

— Slit lamp eye exam every 1–2 years for cataracts

— Annual ECG if QT was prolonged or on QT-prolonging meds

— Ca, phos: every 1–3 months in stage 4–5, monthly on dialysis

— PTH: every 3–6 months

— Alk phos: annually

— Adjust binders, calcimimetic, active D based on trends, not single values

— Take Ca carbonate with meals; citrate any time; avoid co-ingestion with iron, levothyroxine, fluoroquinolones, tetracyclines (4-h separation)

— Recognize hypercalcemia symptoms (stones, bones, abdominal groans, psychic moans) — call provider

— Recognize hypocalcemia recurrence (perioral numbness, cramps)

— Pregnancy planning — Ca demand rises; alert endocrine early

— Medication reconciliation at every visit

— Weight-bearing exercise for bone health

— Smoking cessation, moderate alcohol

— Mental health support — chronic disease burden is significant

CCS pearl: When you "schedule follow-up" on CCS for a hypocalcemia case, choose 2 weeks for stable post-op transient cases, 1 week for ongoing titration, and 48–72 hours if discharging on a new calcitriol dose. The grader rewards specificity, not just "outpatient follow-up."

Acute post-discharge cadence:

Chronic hypoparathyroidism monitoring:

CKD-MBD monitoring (KDIGO):

Patient counseling points:

Rehab/lifestyle:

Ethical, Legal, and Patient Safety Considerations

— Must explicitly disclose risk of transient (10–30%) and permanent (1–3%) hypoparathyroidism, recurrent laryngeal nerve injury, and lifelong Ca/D therapy implications

— Document discussion, especially for total thyroidectomy in benign disease where alternatives exist (lobectomy, surveillance, RAI)

— Consent must include drug interaction implications (levothyroxine + Ca timing)

— IV calcium chloride mislabeling is a sentinel event when given peripherally — institutional protocols should restrict CaCl to central lines / code carts

— Look-alike/sound-alike risks: calcium gluconate vs calcium chloride vials; ensure pharmacy verification

— Smart-pump dose limits for Ca infusions; bedside double-check

— Most common Step 3 trap: post-thyroidectomy patient discharged without clear Ca/calcitriol schedule, presents on day 3 with tetany or seizure

— Mitigation: medication reconciliation, written tapering schedule, scheduled labs, patient teach-back, pharmacist counseling, follow-up appointment before discharge

— Closed-loop communication with PCP via discharge summary within 48 h

— Pediatric rickets from nutritional vitamin D deficiency in an exclusively breastfed infant whose parents refuse supplementation — consider whether neglect threshold is met; involve social work; many states require reporting if child is harmed

— Elder neglect manifesting as severe nutritional deficiency

— Chronic hypoparathyroidism requires complex, multi-drug daily regimens — assess health literacy, cognitive function, financial access (calcitriol cost), and social support

— Shared decision-making for recombinant PTH given osteosarcoma boxed warning

— Chvostek sensitivity ~25%, specificity ~80% — apply Bayes: a positive test in a low-pretest population yields many false positives. Trousseau more useful for ruling in.

— Use likelihood ratios rather than sensitivity alone for clinical decisions

Board pearl: A patient post-total thyroidectomy who develops carpopedal spasm at home on day 2 after being discharged without prophylactic calcium and calcitriol represents a system-level safety failure, not just clinical bad luck. Step 3 vignettes increasingly test this systems lens — the "right" answer is often a protocolized discharge bundle.

Informed consent for thyroid/parathyroid surgery:

High-alert medication safety:

Transitions of care:

Mandatory reporting and abuse:

Capacity and adherence:

Biostatistics integration:

High-Yield Associations and Rapid-Fire Clinical Facts

— Most common cause overall: vitamin D deficiency

— Most common cause in hospitalized patients: hypoalbuminemia (pseudo) → then hypomagnesemia

— Most common cause of true symptomatic hypocalcemia: post-surgical hypoparathyroidism

— PTH-resistance with high PTH, AHO features: pseudohypoparathyroidism type 1a (GNAS imprinting)

— CaSR activating mutation: autosomal dominant hypocalcemia → high urinary Ca

— CaSR inactivating mutation: familial hypocalciuric hypercalcemia

— 22q11.2 deletion: DiGeorge — cardiac defects, thymic aplasia, hypoparathyroidism

— AIRE mutation: APS-1 — candidiasis, hypoparathyroidism, Addison

— Drug causing hypocalcemia via Mg loss: PPIs, loop diuretics, aminoglycosides, cisplatin, foscarnet

— Drug causing hypocalcemia via bone uptake/antiresorptive: denosumab, IV bisphosphonates

— Drug worsening QT in hypocalcemic patient: macrolides, fluoroquinolones, methadone, ondansetron

— Low Ca, high phos, high PTH, high Cr → CKD

— Low Ca, high phos, low PTH → hypoparathyroidism

— Low Ca, low phos, high PTH, high alk phos → vitamin D deficiency

— Low Ca, low phos, low Mg, high alk phos post-parathyroidectomy → hungry bone

— Low Ca, high phos, high PTH, normal Cr, normal 25-OH D → pseudohypoparathyroidism

— Prolonged QT, T inversions in hypocalcemia

— Short QT in hypercalcemia

— Digoxin + IV Ca: caution, slow infusion

— CaCl: central line only

— Calcium gluconate 10%: 1 g = 93 mg elemental Ca

— Chvostek, Trousseau signs

— Fahr syndrome (basal ganglia calcifications)

— Albright hereditary osteodystrophy (PHP 1a)

— Hungry bone syndrome

Key distinction: Hypocalcemia + low Mg = fix Mg first. Hypocalcemia + high phos = think hypoparathyroidism, CKD, or tumor lysis. Hypocalcemia + low phos = vitamin D deficiency. These three forks solve 90% of board stems.

Quick-fire recall:

Lab pattern shortcuts:

ECG/treatment:

Classic syndromes/eponyms:

Board Question Stem Patterns

— "Patient post-op day 1 from total thyroidectomy with circumoral numbness and carpopedal spasm. Ca 7.2, albumin 4.0..."

— Answer cascade: ionized Ca + Mg + ECG → IV calcium gluconate → start oral Ca + calcitriol → check PTH at 12 h → discharge plan with 72-h labs

— "Chronic alcoholic admitted with seizure, Ca 6.8 despite 2 g IV Ca gluconate..."

— Answer: check Mg (low), replete IV MgSO₄ — calcium will respond

— "Anxious 22-yo with carpopedal spasm during argument, normal total Ca..."

— Answer: respiratory alkalosis → reassurance, rebreathing; ionized Ca low transiently

— "Stage 4 CKD with Ca 7.8, phos 6.2, PTH 480..."

— Answer: lower phos first with non-Ca binder (sevelamer); then add active D; avoid Ca-based binder

— "Patient with aggressive lymphoma started on chemo, develops oliguria, K 6.2, phos 8.0, Ca 7.0..."

— Answer: aggressive IVF, allopurinol/rasburicase, treat hyperK first; do NOT aggressively replete Ca unless symptomatic (precipitates Ca-phos)

— "Trauma patient received 8 units pRBCs, BP dropping, ionized Ca 0.85..."

— Answer: IV Ca gluconate; citrate chelation

— "Short patient with round face, short 4th metacarpals, Ca 7.0, phos 6.0, PTH 220..."

— Answer: PHP 1a; treat with Ca + calcitriol; screen for other hormone resistances (TSH)

— "Breast cancer pt on denosumab presents with paresthesias, Ca 6.5..."

— Answer: IV Ca; check vit D — common omission to give denosumab in vit D-deficient patient

— "3-day-old with seizure, cardiac murmur, no thymic shadow..."

— Answer: 22q11.2 FISH; IV Ca gluconate; irradiated blood products

— "Elderly pt on digoxin with hypocalcemia, given rapid IV Ca, develops bradyarrhythmia..."

— Answer: slow infusion next time

Board pearl: When the stem provides PTH + phos + Ca + Cr, you can solve nearly every hypocalcemia question algorithmically without memorizing rare diseases. Anchor on the PTH direction first — appropriate (high) vs inappropriate (low/normal).

Stem 1 — Post-thyroidectomy hypocalcemia:

Stem 2 — Refractory hypocalcemia in alcoholic:

Stem 3 — Hyperventilating young woman:

Stem 4 — CKD with mineral disorder:

Stem 5 — Tumor lysis:

Stem 6 — Massive transfusion:

Stem 7 — Pseudohypoparathyroidism:

Stem 8 — Denosumab/bisphosphonate:

Stem 9 — DiGeorge in neonate:

Stem 10 — Digoxin caution:

One-Line Recap

Hypocalcemia is a PTH–vitamin D–magnesium triangle disorder where the lab pattern (especially the direction of PTH and phosphate) reveals the cause, severity dictates IV vs oral repletion, and long-term care hinges on cause-specific replacement plus vigilant urinary calcium monitoring to prevent treatment-induced nephrocalcinosis.

— Confirm with ionized Ca or albumin-corrected total Ca

— Always check Mg — replete before chasing Ca

— Branch on PTH: low/normal = hypoparathyroidism, Mg deficiency, or ADH; high = vitamin D deficiency, CKD, or PTH resistance

— ECG every symptomatic patient — look for prolonged QT

— Symptomatic, Ca <7.0, QT prolonged, or tetany → IV calcium gluconate bolus + infusion, telemetry

— Calcium chloride is central-line only — patient safety pearl

— Caution with digoxin co-administration — slow infusion

— Transition to oral Ca (carbonate with meals / citrate if PPI) + calcitriol for hypoparathyroidism or CKD

— Target corrected Ca in low-normal range (8.0–8.5) to limit hypercalciuria

— Monitor 24-h urinary Ca to prevent nephrocalcinosis; add thiazide if hypercalciuric

— Maintain 25-OH D >30 ng/mL; cholecalciferol for nutritional deficiency, calcitriol when 1-α-hydroxylase compromised

— Recombinant PTH for refractory chronic hypoparathyroidism

— Discharge bundle after thyroidectomy: Ca + calcitriol Rx, 72-h lab follow-up, written instructions, endocrine appointment in 1–2 weeks

— Reconcile QT-prolonging and Mg-wasting drugs at every visit

— Document informed consent for parathyroid risk preoperatively

— Genetic counseling for DiGeorge, APS-1, PHP, ADH families

Step 3 management: If you remember nothing else — check magnesium, branch on PTH, and never discharge a fresh thyroidectomy patient without a calcium safety net plus 72-hour lab follow-up. That single habit prevents the majority of preventable readmissions and answers most exam stems on this topic.

Diagnosis essentials:

Acute management essentials:

Chronic management essentials:

System and safety essentials: